0000899243-21-021438.txt : 20210601
0000899243-21-021438.hdr.sgml : 20210601
20210601205936
ACCESSION NUMBER: 0000899243-21-021438
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210527
FILED AS OF DATE: 20210601
DATE AS OF CHANGE: 20210601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUSSAIN IQBAL J
CENTRAL INDEX KEY: 0001862050
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40445
FILM NUMBER: 21987392
MAIL ADDRESS:
STREET 1: C/O CENTESSA PHARMACEUTICALS PLC
STREET 2: D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3FH
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc
CENTRAL INDEX KEY: 0001847903
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: THE DOROTHY HODGKIN BUILDING
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: BABRAHAM, CAMBRIDGE
STATE: X0
ZIP: CB22 3FH
BUSINESS PHONE: 44 (0)7767 003904
MAIL ADDRESS:
STREET 1: THE DOROTHY HODGKIN BUILDING
STREET 2: BABRAHAM RESEARCH CAMPUS
CITY: BABRAHAM, CAMBRIDGE
STATE: X0
ZIP: CB22 3FH
FORMER COMPANY:
FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd
DATE OF NAME CHANGE: 20210224
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-27
0
0001847903
Centessa Pharmaceuticals plc
CNTA
0001862050
HUSSAIN IQBAL J
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE
X0
WA14 2DT
UNITED KINGDOM
0
1
0
0
General Counsel
Share Option (right to buy)
5.84
2021-02-19
4
A
0
333559
0.00
A
2031-02-19
Ordinary Shares
333559
333559
D
Share Option (right to buy)
9.42
2021-04-20
4
A
0
166779
0.00
A
2031-04-20
Ordinary Shares
166779
166779
D
Share Option (right to buy)
20.00
2021-05-27
4
A
0
100000
0.00
A
2031-05-27
Ordinary Shares
100000
100000
D
On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3
25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
25% of the shares subject to such option shall vest and become exercisable on February 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
/s/ Marella Thorell, attorney-in-fact
2021-06-01